Predict your next investment

Corporation
avalon-globocare.com

See what CB Insights has to offer

Partners & Customers

10

About Avalon Globocare

Avalon Globocare is a global developer of cell-based technologies.

Avalon Globocare Headquarter Location

4400 Route 9 South Suite 3100

Freehold, New Jersey, 7728,

United States

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Avalon Globocare News

Avalon GloboCare, Lu Daopei Hematology Institute Partner to Develop Cell Therapy CDx

May 18, 2022

Save for later NEW YORK – Cell-based drug developer Avalon GloboCare said Wednesday that it has signed a memorandum of understanding with Lu Daopei Hematology Institute to co-develop precision companion diagnostics for chimeric antigen receptor (CAR)-T cell therapies. Under the deal, the company plans to work with China’s LDHI to explore CDx for both its ongoing and future cellular immunotherapy-related clinical programs. In support of this, Avalon also announced that it has appointed LDHI Executive President Hongxing Liu to its scientific and clinical advisory board. "There is a need for better, faster ways to assess patients' immune profiles to provide personalized immunotherapies," Liu said in a statement. "Patients with cancer whose care incorporates the use of appropriate companion diagnostics as part of their initial assessment have historically seen a greater survival benefit than those who were not tested," he added. Freehold, New Jersey-based Avalon called LDHI "a premiere hematology research institute" with expert capabilities for diagnostics development, including genomic, proteomic, transcriptomic, and metabolomic platforms. "LDHI will be an ideal partner that has the expertise and capabilities to conduct laboratory and analytic work on cancer biomarkers and precision medicine, as well as access to the clinical and bioinformatics database of the Lu Daopei Hospital," David Jin, Avalon's president and CEO, said in a statement. According to the company, the agreement with LDHI is subject to negotiation and execution of definitive documentation acceptable to both parties.

Avalon Globocare Acquisitions

2 Acquisitions

Avalon Globocare acquired 2 companies. Their latest acquisition was Senlang Biotech on June 14, 2021.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

6/14/2021

Private Equity

$99M

$29.68M

Acquired

2

10/30/2017

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/14/2021

10/30/2017

Investment Stage

Private Equity

Companies

Subscribe to see more

Valuation

$99M

$99M

Total Funding

$29.68M

Note

Acquired

Subscribe to see more

Sources

2

10

Avalon Globocare Partners & Customers

10 Partners and customers

Avalon Globocare has 10 strategic partners and customers. Avalon Globocare recently partnered with BOKU on December 12, 2020.

Date

Type

Business Partner

Country

News Snippet

Sources

12/30/2020

Partner

Austria

1

6/25/2020

Partner

Austria

Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate :: Avalon GloboCare Corp. (AVCO)

This strategic partnership with University of Natural Resources and Life Sciences leverages Avalon GloboCare Corp. 's expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at University of Natural Resources and Life Sciences .

1

6/25/2020

Partner

Austria

Avalon GloboCare Achieves Milestones In Advancing Novel Intranasal And Oral COVID-19 Vaccine Candidate

This strategic partnership with University of Natural Resources and Life Sciences leverages Avalon GloboCare Corp. 's expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at University of Natural Resources and Life Sciences .

1

4/28/2020

Partner

Subscribe to see more

Subscribe to see more

10

4/28/2020

Partner

Subscribe to see more

Subscribe to see more

10

Date

12/30/2020

6/25/2020

6/25/2020

4/28/2020

4/28/2020

Type

Partner

Partner

Partner

Partner

Partner

Business Partner

Country

Austria

Austria

Austria

News Snippet

Avalon GloboCare Achieves Milestones in Advancing Novel Intranasal and Oral COVID-19 Vaccine Candidate :: Avalon GloboCare Corp. (AVCO)

This strategic partnership with University of Natural Resources and Life Sciences leverages Avalon GloboCare Corp. 's expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at University of Natural Resources and Life Sciences .

Avalon GloboCare Achieves Milestones In Advancing Novel Intranasal And Oral COVID-19 Vaccine Candidate

This strategic partnership with University of Natural Resources and Life Sciences leverages Avalon GloboCare Corp. 's expertise and resources in bio-manufacturing infrastructure and clinical study implementation with the scientific capabilities and deep experience of the laboratories of Professors Sleytr and Ehmoser at University of Natural Resources and Life Sciences .

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Sources

1

1

1

10

10

Avalon Globocare Team

1 Team Member

Avalon Globocare has 1 team member, including current Chief Financial Officer, Luisa Ingargiola.

Name

Work History

Title

Status

Luisa Ingargiola

Chief Financial Officer

Current

Name

Luisa Ingargiola

Work History

Title

Chief Financial Officer

Status

Current

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.